<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">41022731</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Effect of the gut microbiota-derived tryptophan metabolite indole-3-acetic acid in pneumonia.</ArticleTitle><Pagination><StartPage>8565</StartPage><MedlinePgn>8565</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-025-63611-y</ELocationID><Abstract><AbstractText>Gut microbiota influence the severity of pneumonia by producing metabolites that enhance systemic and pulmonary immune responses. Preclinical studies suggested that gut microbiota-derived indoles have protective effects against numerous diseases, including influenza and abdominal infections. However, the precise role of tryptophan metabolites during pneumonia is unknown. Here, we perform translational analyses in a large general-population cohort (n&#x2009;=&#x2009;13,464), critically ill patients with severe community-acquired pneumonia (CAP; n&#x2009;=&#x2009;158; NCT01905033), a randomized human intervention trial on antibiotic-mediated microbiota modulation (NCT03051698), and mice to investigate the effects of tryptophan metabolites, specifically indole-3-acetic acid (IAA), on pneumonia. In the population-based cohort, baseline IAA is associated with a higher risk of future hospital admission for pneumonia (cause-specific hazard ratio 1.15, 95% confidence interval 1.09-1.22 p&#x2009;&lt;&#x2009;0.0001). In patients with severe CAP higher levels of IAA are associated with increased mortality, independent from potential confounders (hazard ratio 1.30 per log2 increase, 95% confidence interval 1.02-1.68, p&#x2009;=&#x2009;0.037). In a mouse model of bacterial pneumonia, IAA supplementation aggravates pulmonary damage while reducing systemic dissemination, which is mediated by the aryl hydrocarbon receptor (AhR) and increased release of reactive oxygen species from neutrophils. In summary, these findings from general population and severe pneumonia cohorts, and murine pneumonia experiments, show that the gut microbiota-derived tryptophan metabolite IAA affects pneumonia, suggesting that various indoles may have diverging, context-dependent effects.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kullberg</LastName><ForeName>Robert F J</ForeName><Initials>RFJ</Initials><Identifier Source="ORCID">0000-0001-8269-9887</Identifier><AffiliationInfo><Affiliation>Center for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. r.f.j.kullberg@amsterdamumc.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam institute for Immunology and Infectious diseases, Amsterdam, the Netherlands. r.f.j.kullberg@amsterdamumc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Linge</LastName><ForeName>Christine C A</ForeName><Initials>CCA</Initials><AffiliationInfo><Affiliation>Center for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam institute for Immunology and Infectious diseases, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haak</LastName><ForeName>Bastiaan W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>Center for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam institute for Immunology and Infectious diseases, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Prasanjit S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Center for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam institute for Immunology and Infectious diseases, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butler</LastName><ForeName>Joe M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0001-6781-6408</Identifier><AffiliationInfo><Affiliation>Center for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam institute for Immunology and Infectious diseases, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolff</LastName><ForeName>Nora</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Center for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam institute for Immunology and Infectious diseases, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Engelen</LastName><ForeName>Tjitske S R</ForeName><Initials>TSR</Initials><AffiliationInfo><Affiliation>Center for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam institute for Immunology and Infectious diseases, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sikkens</LastName><ForeName>Jonne J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0001-5481-5596</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Section Acute and General Internal Medicine, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bomers</LastName><ForeName>Marije K</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0003-0399-6926</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lef&#xe8;vre</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>UMR 1253, iBrain, INSERM, University of Tours, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cremer</LastName><ForeName>Olaf L</ForeName><Initials>OL</Initials><Identifier Source="ORCID">0000-0003-4264-1108</Identifier><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roelofs</LastName><ForeName>Joris J T H</ForeName><Initials>JJTH</Initials><AffiliationInfo><Affiliation>Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sovran</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology, Endocrinology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatric Surgery, Amsterdam Reproduction and Development Research Institute, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emma Center for Personalized Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Wijngaard</LastName><ForeName>Ren&#xe9;</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology, Endocrinology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Vos</LastName><ForeName>Alex F</ForeName><Initials>AF</Initials><Identifier Source="ORCID">0000-0002-2472-3014</Identifier><AffiliationInfo><Affiliation>Center for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam institute for Immunology and Infectious diseases, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Jonge</LastName><ForeName>Wouter J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology, Endocrinology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General, Visceral, Thoracic and Vascular Surgery, University Hospital Bonn, Bonn, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Poll</LastName><ForeName>Tom</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-9199-5079</Identifier><AffiliationInfo><Affiliation>Center for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam institute for Immunology and Infectious diseases, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiersinga</LastName><ForeName>W Joost</ForeName><Initials>WJ</Initials><Identifier Source="ORCID">0000-0003-2277-1343</Identifier><AffiliationInfo><Affiliation>Center for Infection and Molecular Medicine (CIMM), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam institute for Immunology and Infectious diseases, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/N003284/1, MC-UU_12015/1 and MC_UU_00006/1</GrantID><Agency>RCUK | Medical Research Council (MRC)</Agency><Country/></Grant><Grant><GrantID>C864/A14136</GrantID><Agency>Cancer Research UK (CRUK)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>6U1S09C61L</RegistryNumber><NameOfSubstance UI="C030737">indoleacetic acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007210">Indoleacetic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>8DUH1N11BX</RegistryNumber><NameOfSubstance UI="D014364">Tryptophan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007210" MajorTopicYN="Y">Indoleacetic Acids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011014" MajorTopicYN="Y">Pneumonia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018410" MajorTopicYN="Y">Pneumonia, Bacterial</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014364" MajorTopicYN="Y">Tryptophan</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: WdJ reports grants from the EU and ZonMW, and is a shareholder and board member of AIBiomics BV. WJW reports grants from the EU and ZonMw/NWO, and ad hoc consultancy for AstraZeneca and Shionogi (fees paid to the host institution), outside the submitted work. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>5</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>5</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>29</Day><Hour>23</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41022731</ArticleId><ArticleId IdType="doi">10.1038/s41467-025-63611-y</ArticleId><ArticleId IdType="pii">10.1038/s41467-025-63611-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>GBD 2019 Diseases and Injuries Collaborators Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet 396, 1204&#x2013;1222 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30925-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres, A. et al. Pneumonia. Nat. Rev. Dis. Prim. 7, 25 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33833230</ArticleId><ArticleId IdType="doi">10.1038/s41572-021-00259-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Wunderink, R. G. &amp; Waterer, G. Advances in the causes and management of community acquired pneumonia in adults. BMJ 358, j2471 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28694251</ArticleId><ArticleId IdType="doi">10.1136/bmj.j2471</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuijt, T. J. et al. The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. Gut 65, 575&#x2013;583 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26511795</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2015-309728</ArticleId></ArticleIdList></Reference><Reference><Citation>Haak, B. W. &amp; Wiersinga, W. J. The role of the gut microbiota in sepsis. Lancet Gastroenterol. Hepatol. 2, 135&#x2013;143 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28403983</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(16)30119-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichinohe, T. et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc. Natl. Acad. Sci. USA 108, 5354&#x2013;5359 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21402903</ArticleId><ArticleId IdType="pmc">3069176</ArticleId><ArticleId IdType="doi">10.1073/pnas.1019378108</ArticleId></ArticleIdList></Reference><Reference><Citation>Sencio, V. et al. Gut dysbiosis during influenza contributes to pulmonary pneumococcal superinfection through altered short-chain fatty acid production. Cell Rep. 30, 2934&#x2013;2947.e6 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32130898</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2020.02.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Guern, R. et al. Gut colonisation with multidrug-resistant Klebsiella pneumoniae worsens pseudomonas aeruginosa lung infection. Nat. Commun. 14, 78 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36604442</ArticleId><ArticleId IdType="pmc">9816093</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-35767-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard-Raichon, L. et al. Gut microbiome dysbiosis in antibiotic-treated COVID-19 patients is associated with microbial translocation and bacteremia. Nat. Commun. 13, 5926 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36319618</ArticleId><ArticleId IdType="pmc">9626559</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-33395-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Kullberg, R. F. J. et al. Rectal bacteriome and virome signatures and clinical outcomes in community-acquired pneumonia: an exploratory study. EclinicalMedicine 39, 101074 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34611613</ArticleId><ArticleId IdType="pmc">8478680</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2021.101074</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeoh, Y. K. et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut 70, 698&#x2013;706 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33431578</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2020-323020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kullberg R. F. J. et al. Association between butyrate-producing gut bacteria and the risk of infectious disease hospitalisation: results from two observational, population-based microbiome studies. Lancet Microbe. 5, 100864 (2024).</Citation></Reference><Reference><Citation>Budden, K. F. et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat. Rev. Microbiol 15, 55&#x2013;63 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27694885</ArticleId><ArticleId IdType="doi">10.1038/nrmicro.2016.142</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd6;z&#xe7;am M., Lynch S. V. The gut-airway microbiome axis in health and respiratory diseases. Nat. Rev. Microbiol. 22, 492&#x2212;506 (2024).</Citation></Reference><Reference><Citation>Agus, A., Planchais, J. &amp; Sokol, H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe 23, 716&#x2013;724 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29902437</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2018.05.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Roager, H. M. &amp; Licht, T. R. Microbial tryptophan catabolites in health and disease. Nat. Commun. 9, 3294 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30120222</ArticleId><ArticleId IdType="pmc">6098093</ArticleId><ArticleId IdType="doi">10.1038/s41467-018-05470-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamas, B. et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat. Med. 22, 598&#x2013;605 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27158904</ArticleId><ArticleId IdType="pmc">5087285</ArticleId><ArticleId IdType="doi">10.1038/nm.4102</ArticleId></ArticleIdList></Reference><Reference><Citation>Michaudel, C. et al. Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases. Gut 72, 1296&#x2013;1307 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36270778</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2022-327337</ArticleId></ArticleIdList></Reference><Reference><Citation>Natividad, J. M. et al. Impaired aryl hydrocarbon receptor ligand production by the gut microbiota is a key factor in metabolic syndrome. Cell Metab. 28, 737&#x2013;749.e4 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30057068</ArticleId><ArticleId IdType="doi">10.1016/j.cmet.2018.07.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, Y. et al. Interplay between diet, circulating indolepropionate concentrations and cardiometabolic health in US populations. Gut 72, 2260&#x2013;2271 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37739776</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2023-330410</ArticleId></ArticleIdList></Reference><Reference><Citation>Tintelnot, J. et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615, 168&#x2013;174 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36813961</ArticleId><ArticleId IdType="pmc">9977685</ArticleId><ArticleId IdType="doi">10.1038/s41586-023-05728-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan, Z. et al. Multi-omics analyses of airway host-microbe interactions in chronic obstructive pulmonary disease identify potential therapeutic interventions. Nat. Microbiol 7, 1361&#x2013;1375 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35995842</ArticleId><ArticleId IdType="doi">10.1038/s41564-022-01196-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, H. et al. Gut microbiota-derived tryptophan metabolites alleviate allergic asthma inflammation in ovalbumin-induced mice. Foods 13, 1336 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38731707</ArticleId><ArticleId IdType="pmc">11082989</ArticleId><ArticleId IdType="doi">10.3390/foods13091336</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres, A., Peetermans, W. E., Viegi, G. &amp; Blasi, F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 68, 1057&#x2013;1065 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24130229</ArticleId><ArticleId IdType="doi">10.1136/thoraxjnl-2013-204282</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, Z. B. et al. Gut microbiota-derived indole 3-propionic acid partially activates aryl hydrocarbon receptor to promote macrophage phagocytosis and attenuate septic injury. Front. Cell Infect. Microbiol. 12, 1015386 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36299625</ArticleId><ArticleId IdType="pmc">9589056</ArticleId><ArticleId IdType="doi">10.3389/fcimb.2022.1015386</ArticleId></ArticleIdList></Reference><Reference><Citation>Heumel, S. et al. Shotgun metagenomics and systemic targeted metabolomics highlight indole-3-propionic acid as a protective gut microbial metabolite against influenza infection. Gut Microbes 16, 2325067 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38445660</ArticleId><ArticleId IdType="pmc">10936607</ArticleId><ArticleId IdType="doi">10.1080/19490976.2024.2325067</ArticleId></ArticleIdList></Reference><Reference><Citation>Major, J. et al. Endothelial AHR activity prevents lung barrier disruption in viral infection. Nature 621, 813&#x2013;820 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37587341</ArticleId><ArticleId IdType="pmc">7615136</ArticleId><ArticleId IdType="doi">10.1038/s41586-023-06287-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo, Y. D. &amp; Wargo, J. A. From bugs to drugs: bacterial 3-IAA enhances efficacy of chemotherapy in pancreatic cancer. Cell Rep. Med 4, 101039 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37196631</ArticleId><ArticleId IdType="pmc">10213830</ArticleId><ArticleId IdType="doi">10.1016/j.xcrm.2023.101039</ArticleId></ArticleIdList></Reference><Reference><Citation>Barranco, C. Tryptophan metabolite improves PDAC response rates and survival. Nat. Rev. Cancer 23, 272 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36973408</ArticleId><ArticleId IdType="doi">10.1038/s41568-023-00566-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter, J., Armet, A. M., Finlay, B. B. &amp; Shanahan, F. Establishing or exaggerating causality for the gut microbiome: lessons from human microbiota-associated rodents. Cell 180, 221&#x2013;232 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31978342</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2019.12.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietzner, M. et al. Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat. Med 27, 471&#x2013;479 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33707775</ArticleId><ArticleId IdType="pmc">8127079</ArticleId><ArticleId IdType="doi">10.1038/s41591-021-01266-0</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vught, L. A. et al. Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA 315, 1469&#x2013;1479 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26975785</ArticleId><ArticleId IdType="doi">10.1001/jama.2016.2691</ArticleId></ArticleIdList></Reference><Reference><Citation>Scicluna, B. P. et al. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. Lancet Respir. Med. 5, 816&#x2013;826 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28864056</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(17)30294-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Michels, E. H. A. et al. Association between age and the host response in critically ill patients with sepsis. Crit. Care 26, 385 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36514130</ArticleId><ArticleId IdType="pmc">9747080</ArticleId><ArticleId IdType="doi">10.1186/s13054-022-04266-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Sikkens, J. J. et al. Serologic surveillance and phylogenetic analysis of SARS-CoV-2 infection among hospital health care workers. JAMA Netw. Open 4, e2118554 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34319354</ArticleId><ArticleId IdType="pmc">9437910</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.18554</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelman, B. et al. Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination. EbioMedicine 72, 103589 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34571363</ArticleId><ArticleId IdType="pmc">8461365</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2021.103589</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefevre, A. et al. Validation of a global quantitative analysis methodology of tryptophan metabolites in mice using LC-MS. Talanta 195, 593&#x2013;598 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30625588</ArticleId><ArticleId IdType="doi">10.1016/j.talanta.2018.11.094</ArticleId></ArticleIdList></Reference><Reference><Citation>Chanderraj, R. et al. In critically ill patients, anti-anaerobic antibiotics increase risk of adverse clinical outcomes. Eur. Respir. J. 61, 2200910 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36229047</ArticleId><ArticleId IdType="pmc">9909213</ArticleId><ArticleId IdType="doi">10.1183/13993003.00910-2022</ArticleId></ArticleIdList></Reference><Reference><Citation>Kullberg R. F. J. et al. Empirical antibiotic therapy for sepsis: save the anaerobic microbiota. Lancet Respir. Med. 13, 92&#x2212;100 (2024).</Citation></Reference><Reference><Citation>Wu, P. et al. The trans-omics landscape of COVID-19. Nat. Commun. 12, 4543 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34315889</ArticleId><ArticleId IdType="pmc">8316550</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-24482-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosyakovsky, L. B. et al. Machine learning approaches to the human metabolome in sepsis identify metabolic links with survival. Intensive Care Med. Exp. 10, 24 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35710638</ArticleId><ArticleId IdType="pmc">9203139</ArticleId><ArticleId IdType="doi">10.1186/s40635-022-00445-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Engelen, T. S. R. et al. CAST study group. Gut microbiome modulation by antibiotics in adult asthma: a human proof-of-concept intervention trial. Clin. Gastroenterol. Hepatol. 20, 1404&#x2013;1407.e4 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34303860</ArticleId><ArticleId IdType="doi">10.1016/j.cgh.2021.07.030</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolff, N. S., Jacobs, M. C., Wiersinga, W. J. &amp; Hugenholtz, F. Pulmonary and intestinal microbiota dynamics during gram-negative pneumonia-derived sepsis. Intensive Care Med Exp. 9, 35 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34250564</ArticleId><ArticleId IdType="pmc">8272965</ArticleId><ArticleId IdType="doi">10.1186/s40635-021-00398-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Claushuis, T. A. M. et al. Platelet glycoprotein VI aids in local immunity during pneumonia-derived sepsis caused by gram-negative bacteria. Blood 131, 864&#x2013;876 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29187378</ArticleId><ArticleId IdType="doi">10.1182/blood-2017-06-788067</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin, W., Liu, Z., van der Poll, T. &amp; de Vos, A. F. Induction of acute or disseminating bacterial pneumonia in mice and sampling of infected organs for studying the host response to bacterial pneumonia. Bio Protoc. 12, e4287 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35118178</ArticleId><ArticleId IdType="pmc">8769758</ArticleId><ArticleId IdType="doi">10.21769/BioProtoc.4287</ArticleId></ArticleIdList></Reference><Reference><Citation>Podschun, R. &amp; Ullmann, U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin. Microbiol. Rev. 11, 589&#x2013;603 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9767057</ArticleId><ArticleId IdType="pmc">88898</ArticleId><ArticleId IdType="doi">10.1128/CMR.11.4.589</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, M. et al. Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. Lancet Infect. Dis. 22, 401&#x2013;412 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34767753</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(21)00399-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji, Y., Gao, Y., Chen, H., Yin, Y. &amp; Zhang, W. Indole-3-acetic acid alleviates nonalcoholic fatty liver disease in mice via attenuation of hepatic lipogenesis, and oxidative and inflammatory stress. Nutrients 11, 2062 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31484323</ArticleId><ArticleId IdType="pmc">6769627</ArticleId><ArticleId IdType="doi">10.3390/nu11092062</ArticleId></ArticleIdList></Reference><Reference><Citation>de Melo, P. ires, Curi, M., Miyasaka, T. C., Palanch, C. K. &amp; Curi, A. C. R. Effect of indole acetic acid on oxygen metabolism in cultured rat neutrophil. Gen. Pharm. 31, 573&#x2013;578 (1998).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-3623(98)00032-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Z. et al. Bruton&#x2019;s Tyrosine kinase in neutrophils Is crucial for host defense against Klebsiella pneumoniae. J. Innate Immun. 15, 1&#x2013;15 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">35537415</ArticleId><ArticleId IdType="doi">10.1159/000524583</ArticleId></ArticleIdList></Reference><Reference><Citation>Pechous, R. D. With friends like these: the complex role of neutrophils in the progression of severe pneumonia. Front. Cell Infect. Microbiol. 7, 160 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28507954</ArticleId><ArticleId IdType="pmc">5410563</ArticleId><ArticleId IdType="doi">10.3389/fcimb.2017.00160</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar-Hari, M. et al. Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies. Lancet Respir. Med. 12, 323&#x2013;336 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38408467</ArticleId><ArticleId IdType="pmc">11025021</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(23)00468-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue, C. et al. Tryptophan metabolism in health and disease. Cell Metab. 35, 1304&#x2013;1326 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37352864</ArticleId><ArticleId IdType="doi">10.1016/j.cmet.2023.06.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Su, X. et al. Gut microbiota-derived metabolite 3-idoleacetic acid together with LPS induces IL-35<sup>+</sup> B cell generation. Microbiome 10, 13 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35074011</ArticleId><ArticleId IdType="pmc">8785567</ArticleId><ArticleId IdType="doi">10.1186/s40168-021-01205-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao, J. et al. Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. Front Cell Infect. Microbiol. 8, 13 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29468141</ArticleId><ArticleId IdType="pmc">5808205</ArticleId><ArticleId IdType="doi">10.3389/fcimb.2018.00013</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, F. et al. Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications. Nat. Rev. Gastroenterol. Hepatol. 20, 323&#x2013;337 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36271144</ArticleId><ArticleId IdType="doi">10.1038/s41575-022-00698-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlechte, J. et al. Dysbiosis of a microbiota-immune metasystem in critical illness is associated with nosocomial infections. Nat. Med. 29, 1017&#x2013;1027 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36894652</ArticleId><ArticleId IdType="pmc">10115642</ArticleId><ArticleId IdType="doi">10.1038/s41591-023-02243-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha A. K. et al. Dietary fibre directs microbial tryptophan metabolism via metabolic interactions in the gut microbiota. Nat. Microbiol. 9, 1964&#x2212;1978 (2024).</Citation></Reference><Reference><Citation>Lamas, B., Natividad, J. M. &amp; Sokol, H. Aryl hydrocarbon receptor and intestinal immunity. Mucosal Immunol. 11, 1024&#x2013;1038 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29626198</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolff, N. S. et al. Vendor effects on murine gut microbiota and its influence on lipopolysaccharide-induced lung inflammation and gram-negative pneumonia. Intensive Care Med Exp. 8, 47 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32840685</ArticleId><ArticleId IdType="pmc">7447702</ArticleId><ArticleId IdType="doi">10.1186/s40635-020-00336-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Villarino, N. F. et al. Composition of the gut microbiota modulates the severity of malaria. Proc. Natl. Acad. Sci. USA 113, 2235&#x2013;2240 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26858424</ArticleId><ArticleId IdType="pmc">4776451</ArticleId><ArticleId IdType="doi">10.1073/pnas.1504887113</ArticleId></ArticleIdList></Reference><Reference><Citation>Day, N. et al. EPIC-Norfolk: study design and characteristics of the cohort. European prospective investigation of cancer. Br. J. Cancer 80, 95&#x2013;103 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10466767</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein Klouwenberg, P. M. et al. Interobserver agreement of centers for disease control and prevention criteria for classifying infections in critically ill patients. Crit. Care Med. 41, 2373&#x2013;2378 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23921277</ArticleId><ArticleId IdType="doi">10.1097/CCM.0b013e3182923712</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer, M. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315, 801&#x2013;810 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26903338</ArticleId><ArticleId IdType="pmc">4968574</ArticleId><ArticleId IdType="doi">10.1001/jama.2016.0287</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereverzeva, L. et al. Blood leukocyte transcriptomes in Gram-positive and Gram-negative community-acquired pneumonia. Eur. Respir. J. 59, 2101856 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34446464</ArticleId><ArticleId IdType="doi">10.1183/13993003.01856-2021</ArticleId></ArticleIdList></Reference><Reference><Citation>Brands, X. et al. Plasma ferritin as marker of macrophage activation-like syndrome in critically ill patients with community-acquired pneumonia. Crit. Care Med. 49, 1901&#x2013;1911 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33935163</ArticleId><ArticleId IdType="doi">10.1097/CCM.0000000000005072</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouchane, O. et al. The plasma lipidomic landscape in patients with sepsis due to community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 209, 973&#x2013;986 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38240721</ArticleId><ArticleId IdType="pmc">12039242</ArticleId><ArticleId IdType="doi">10.1164/rccm.202308-1321OC</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, J. et al. Effect of C1-inhibitor in adults with mild asthma: a randomized controlled trial. Allergy 75, 953&#x2013;955 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31535384</ArticleId><ArticleId IdType="doi">10.1111/all.14053</ArticleId></ArticleIdList></Reference><Reference><Citation>Lankelma, J. M. et al. Antibiotic-induced gut microbiota disruption during human endotoxemia: a randomised controlled study. Gut 66, 1623&#x2013;1630 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">27307305</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2016-312132</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris, V. C. et al. Effect of antibiotic-mediated microbiome modulation on rotavirus vaccine immunogenicity: a human, randomized-control proof-of-concept trial. Cell Host Microbe 24, 197&#x2013;207.e4 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30092197</ArticleId><ArticleId IdType="pmc">11514417</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2018.07.005</ArticleId></ArticleIdList></Reference><Reference><Citation>de Porto, A. P. et al. Bruton&#x2019;s Tyrosine kinase-mediated signaling in myeloid cells is required for protective innate immunity during pneumococcal pneumonia. Front. Immunol. 12, 723967 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34552589</ArticleId><ArticleId IdType="pmc">8450579</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2021.723967</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin, W. et al. Role of myeloid tet methylcytosine dioxygenase 2 in pulmonary and peritoneal inflammation induced by lipopolysaccharide and peritonitis induced by Escherichia coli. Cells 11, 82 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">35011643</ArticleId><ArticleId IdType="pmc">8750455</ArticleId><ArticleId IdType="doi">10.3390/cells11010082</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahlgren, C., Karlsson, A. &amp; Bylund, J. Measurement of respiratory burst products generated by professional phagocytes. Methods Mol. Biol. 412, 349&#x2013;363 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18453123</ArticleId><ArticleId IdType="doi">10.1007/978-1-59745-467-4_23</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedges, L. V. Distribution theory for glass&#x2019;s estimator of effect size and related estimators. J. Educ. Stat. 6, 107&#x2013;128 (1981).</Citation><ArticleIdList><ArticleId IdType="doi">10.3102/10769986006002107</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabregat, A. et al. The reactome pathway knowledgebase. Nucleic Acids Res. 46, D649&#x2013;D655 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29145629</ArticleId><ArticleId IdType="doi">10.1093/nar/gkx1132</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, G. &amp; He, Q. Y. ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. Mol. Biosyst. 12, 477&#x2013;479 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26661513</ArticleId><ArticleId IdType="doi">10.1039/C5MB00663E</ArticleId></ArticleIdList></Reference><Reference><Citation>Kullberg, R. F. J., van Linge, C. C. A. et al. Effect of the gut microbiota-derived tryptophan metabolite indole-3-acetic acid in pneumonia. Github Repos. https://doi.org/10.5281/zenodo.15836609 (2025).</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.15836609</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>